Overview

Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
0
Participant gender:
All
Summary
There is a lack of data on the prognostic importance of silent ischemia in totally asymptomatic subjects without history of coronary artery disease (CAD), and, particularly, on a possible benefit of medical therapy in such patients. SWISSI 1 therefore recruits totally asymptomatic subjects older than 40 years of age without any history of CAD but one cardiovascular risk factor with documented silent ischemia. Participants are randomized to open antianginal drug therapy and risk factor control versus only risk factor management and followed up for ≥ 10 years.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Luzerner Kantonsspital
Treatments:
Amlodipine
Aspirin
Bisoprolol
Molsidomine
Criteria
Inclusion Criteria:

- Documented silent myocardial ischemia type I

- At least one cardiovascular risk factor

Exclusion Criteria:

- History of cardiovascular disease